Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Deferred Tax Liability (2023 - 2025)

Ascendis Pharma A (ASND) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $11.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability rose 44.43% to $11.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.2 million through Dec 2025, up 44.43% year-over-year, with the annual reading at $11.2 million for FY2025, 44.43% up from the prior year.
  • Non-Current Deferred Tax Liability hit $11.2 million in Q4 2025 for Ascendis Pharma A, up from $7.8 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $11.2 million in Q4 2025 to a low of $6.3 million in Q4 2023.
  • Historically, Non-Current Deferred Tax Liability has averaged $8.4 million across 3 years, with a median of $7.8 million in 2024.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: increased 23.64% in 2024 and later skyrocketed 44.43% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at $6.3 million in 2023, then rose by 23.64% to $7.8 million in 2024, then skyrocketed by 44.43% to $11.2 million in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for ASND at $11.2 million in Q4 2025, $7.8 million in Q4 2024, and $6.3 million in Q4 2023.